EMA Authorised: Prolia (denosumab) — Amgen Europe B.V.

View source ↗

Summary

The EMA authorised Prolia (denosumab) from Amgen Europe B.V. for osteoporosis, including postmenopausal osteoporosis. The decision date was 17/07/2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Prolia (denosumab)

Snippet

Status: Authorised. Therapeutic area: Bone Resorption;Osteoporosis, Postmenopausal;Osteoporosis. MAH: Amgen Europe B.V.. Decision date: 17/07/2025